(NASDAQ: TGTX) Tg Therapeutics's forecast annual revenue growth rate of 27.79% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 29.39%, and while it is forecast to beat the US market's average forecast revenue growth rate of 12.3%.
Tg Therapeutics's revenue in 2026 is $799,536,000.On average, 10 Wall Street analysts forecast TGTX's revenue for 2026 to be $149,932,668,104, with the lowest TGTX revenue forecast at $142,507,288,343, and the highest TGTX revenue forecast at $157,967,262,696. On average, 10 Wall Street analysts forecast TGTX's revenue for 2027 to be $205,877,876,285, with the lowest TGTX revenue forecast at $182,764,449,282, and the highest TGTX revenue forecast at $230,828,131,924.
In 2028, TGTX is forecast to generate $253,788,489,874 in revenue, with the lowest revenue forecast at $221,337,850,638 and the highest revenue forecast at $302,311,379,675.